0001209191-19-041095.txt : 20190703
0001209191-19-041095.hdr.sgml : 20190703
20190703162427
ACCESSION NUMBER: 0001209191-19-041095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190702
FILED AS OF DATE: 20190703
DATE AS OF CHANGE: 20190703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZACCARDELLI DAVID
CENTRAL INDEX KEY: 0001627642
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38135
FILM NUMBER: 19942165
MAIL ADDRESS:
STREET 1: 300 TRI STATE INTERNATIONAL
STREET 2: SUITE 272
CITY: LINCOLNSHIRE
STATE: IL
ZIP: 60069
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001685071
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813858961
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
BUSINESS PHONE: 919-806-4487
MAIL ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
FORMER COMPANY:
FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20160919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-07-02
0
0001685071
Dova Pharmaceuticals Inc.
DOVA
0001627642
ZACCARDELLI DAVID
C/O DOVA PHARMACEUTICALS, INC.
240 LEIGH FARM ROAD, SUITE 245
DURHAM
NC
27707
1
1
0
0
President & CEO
Common Stock
2019-07-02
4
S
0
5899
15.73
D
86473
D
Common Stock
2019-07-02
4
S
0
4551
16.22
D
81922
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $16.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.09 to $16.50 inclusive.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-07-03